Analysis of the Different Therapeutic Effects in 21 Ph
10.19746/j.cnki.issn.1009-2137.2021.01.006
- Author:
Shu-Chun WANG
1
;
Ye GUO
1
;
Xiao-Juan CHEN
1
;
Xiao-Ming LIU
1
;
Min RUAN
1
;
Wen-Yu YANG
1
;
Li ZHANG
1
;
Yao ZOU
1
;
Yu-Mei CHEN
1
;
Xiao-Fan ZHU
2
Author Information
1. State Key Laboratory of Exprerimental Hematology, National Clinical Research Center for Blood Disease, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China.
2. State Key Laboratory of Exprerimental Hematology, National Clinical Research Center for Blood Disease, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China E-mail: xfzhu@ihcams.ac.cn.
- Publication Type:Journal Article
- MeSH:
Aged;
Child;
Female;
Hematopoietic Stem Cell Transplantation;
Humans;
Infant;
Male;
Philadelphia Chromosome;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy*;
Protein Kinase Inhibitors;
Retrospective Studies
- From:
Journal of Experimental Hematology
2021;29(1):38-42
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the outcomes of the children suffered from philadelphia chromosome positive acute lymphoblastic leukemia (Ph
METHODS:21 cases of firstly diagnosed Ph
RESULTS:Among 21 patients, 17 were male and 4 were female with a median age of 8 years old (range, 4-12 years), the median follow-up time was 30 moths (range, 10-133 months). All the patients were treated with chemotherapy induced by the high-risk project of CCLG-ALL 2008. Among 14 patients treated with TKI plus chemotherapy, nine patients achieved complete remission. During 3 months after treatment, patients without complete molecular response or with the second complete remission and intensity desire of transplantation were treated with allo-HSCT, among 9 patients with allo-HSCT, six patients achieved long term survival.
CONCLUSION:At TKI era, TKI combined with strong chemotherapy can make Ph
